GENMAB A/SGMABEarnings & Financial Report
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
GMAB Q2 2025 Key Financial Metrics
营收
$925.0M
毛利润
$868.0M
营业利润
$360.0M
净利润
$336.0M
毛利率
93.8%
营业利润率
38.9%
净利率
36.3%
同比增长
18.7%
EPS
$5.42
资金流向
GENMAB A/S Q2 2025 Financial Summary
GENMAB A/S reported revenue of $925.0M (up 18.7% YoY) for Q2 2025, with a net profit of $336.0M (up 65.5% YoY) (36.3% margin). Cost of goods sold was $57.0M, operating expenses totaled $508.0M.
Key Financial Metrics
| Total Revenue | $925.0M |
|---|---|
| Net Profit | $336.0M |
| Gross Margin | 93.8% |
| Operating Margin | 38.9% |
| Report Period | Q2 2025 |
Revenue Breakdown
GENMAB A/S Q2 2025 revenue of $925.0M breaks down across 9 segments, led by Darzalex at $638.0M (69.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Darzalex | $638.0M | 69.0% |
| Kesimpta | $108.0M | 11.7% |
| Net Product Sales | $101.0M | 10.9% |
| Other | $28.0M | 3.0% |
| Tepezza | $20.0M | 2.2% |
| Reimbursement Revenue | $13.0M | 1.4% |
| Bio N Tech | $11.0M | 1.2% |
| Abb Vie | $5.0M | 0.5% |
| Milestone Revenue | $1.0M | 0.1% |
GENMAB A/S Quarterly Revenue & Net Profit History
GENMAB A/S quarterly results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2025 | $925.0M | +18.7% | $336.0M | 36.3% |
| Q2 2024 | $779.0M | — | $203.0M | 26.1% |
利润表
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 营收 | $779.0M | $925.0M |
| 同比增长 | N/A | 18.7% |
资产负债表
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 总资产 | N/A | $6.46B |
| 总负债 | N/A | $1.16B |
| 股东权益 | $4.45B | $5.30B |